Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

8.620 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,071
Open 8.620
Bid (Size) 8.560 (1,000)
Ask (Size) 8.800 (300)
Prev. Close 8.620
Today's Range 8.620 - 8.620
52wk Range 5.850 - 24.17
Shares Outstanding 26,562,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
Via Investor Brand Network
Topics Artificial Intelligence

Performance

YTD
+37.9%
+37.9%
1 Month
+11.7%
+11.7%
3 Month
+13.9%
+13.9%
6 Month
-10.5%
-10.5%
1 Year
-32.7%
-32.7%

More News

Read More
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
Via Investor Brand Network
Arcturus Therapeutics (NASDAQ:ARCT) Stock Falls After Q4 2025 Revenue Miss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Preview: Arcturus Therapeutics's Earnings ↗
Via Benzinga
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
From BioMedWire
Via GlobeNewswire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Via The Motley Fool
News headline image
These Are the Only 3 Stocks That Cathie Wood Bought Last Week ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus (ARCT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Lawsuit
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics (NASDAQ:ARCT) Reports Mixed Q3 2025 Results, Extends Cash Runway to 2028 ↗
Via Chartmill
News headline image
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
This Molina Healthcare Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday ↗
Via Benzinga
News headline image
Cathie Wood Goes Shopping: 3 Stocks She Just Bought ↗
Via The Motley Fool
Topics ETFs
News headline image
Where Arcturus Therapeutics Stands With Analysts ↗
Via Benzinga
News headline image
Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture ↗
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Arcturus Therapeutics Holdings Inc publicly traded?
Yes, Arcturus Therapeutics Holdings Inc is publicly traded.
What exchange does Arcturus Therapeutics Holdings Inc trade on?
Arcturus Therapeutics Holdings Inc trades on the Nasdaq Stock Market
What is the ticker symbol for Arcturus Therapeutics Holdings Inc?
The ticker symbol for Arcturus Therapeutics Holdings Inc is ARCT on the Nasdaq Stock Market
What is the current price of Arcturus Therapeutics Holdings Inc?
The current price of Arcturus Therapeutics Holdings Inc is 8.620
When was Arcturus Therapeutics Holdings Inc last traded?
The last trade of Arcturus Therapeutics Holdings Inc was at 04/30/26 04:00 PM ET
What is the market capitalization of Arcturus Therapeutics Holdings Inc?
The market capitalization of Arcturus Therapeutics Holdings Inc is 228.97M
How many shares of Arcturus Therapeutics Holdings Inc are outstanding?
Arcturus Therapeutics Holdings Inc has 229M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.